Lonza Pharma & Biotech
Due to the intrinsic enteric properties of Capsugel® Vcaps® Enteric, no coating step is needed. It means that this capsule is a ready-to-use solution that can help you in obtaining significant cost and time savings during pharmaceutical development or compounding.
Capsugel® Vcaps® Enteric Capsule is a fully compliant capsule technology that simplifies drug enteric delivery implementation from early-stage development to commercial manufacturing. The pharmaceutical grades of cellulosic derivatives used in Capsugel® Vcaps® Enteric capsules are approved and have extensive market precedence for use in providing enteric protection. They have been evaluated in-vitro and in-vivo across a number of compounds, which has proven full compliance with relevant European, Japanese and US Pharmacopeia monographs.
Capsugel® Vcaps® Enteric capsules can be utilized to greatly simplify and accelerate prototype development and rapid in-vivo testing of products requiring targeted delivery to the upper GI tract:
- Eliminate coating system preparation and application steps
- Rapid screening and optimization of enteric performance
- Remove dependency of enteric functionality with process variability
- Obviate need for process development of the enteric coating step, process scale-up and validation
Product Description
- Two-piece hard capsule
- Manufactured with pharmaceutical-grade cellulosic derivatives (HPMCAS, HPMC)
Contact Details:
Company name: Lonza Pharma & Biotech
Website: www.capsugel.com/biopharmaceutical-products/vcaps-enteric-capsules
E-mail: solutions.emea@lonza.com
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
